These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37193973)

  • 1. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.
    Tepper SJ; Cirillo J; Kim E; L'Italien G; Tweedie JM; Lodaya K; Riley D; Pathan F; Antaki N; Nathanson BH; McAllister P
    J Headache Pain; 2023 May; 24(1):54. PubMed ID: 37193973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention.
    Regnier SA; Lee XY
    J Med Econ; 2023; 26(1):1072-1080. PubMed ID: 37594778
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Chan TLH; Cowan RP; Woldeamanuel YW
    Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Gross E; Putananickal N; Orsini AL; Schmidt S; Vogt DR; Cichon S; Sandor P; Fischer D
    Trials; 2019 Jan; 20(1):61. PubMed ID: 30654835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
    Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
    JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis.
    Meissner K; Fässler M; Rücker G; Kleijnen J; Hróbjartsson A; Schneider A; Antes G; Linde K
    JAMA Intern Med; 2013 Nov; 173(21):1941-51. PubMed ID: 24126676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
    Gui T; Li H; Zhu F; Wang Q; Zhou X; Xue Q
    Headache; 2022 Nov; 62(10):1281-1292. PubMed ID: 36373822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis.
    Swerts DB; Benedetti F; Peres MFP
    Pain; 2022 Mar; 163(3):415-424. PubMed ID: 34252914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
    Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
    Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
    Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U
    J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
    Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
    J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.